Factor IX (F9) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 02 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Hemophilia B Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for Factor IX (F9) drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen (Wild-Type & Mutant) Human Factor IX WT & Padua (R338L) Mutant Proteins; high purity (>95%), endotoxin <1EU/µg, HEK293 expressed (native glycosylation), Sequence Verified. Includes hemophilia B mutant panel. View Factor IX Products
Gene Delivery Factor IX Promise-ORF / Lentivirus; full-length F9 ORF for stable cell lines, codon-optimized. View Factor IX Products
Benchmark Antibody Anti-Factor IX (non-inhibitory, clinical benchmark sequence); recombinant positive control for PK/ADA assays. View Factor IX Products
Validator Factor IX siRNA Set; for knockdown verification in expression assays. View Factor IX Products
Species Orthologs Cynomolgus/Macaque and Mouse Factor IX proteins for cross-species PK/PD and immunogenicity studies. View Factor IX Products
Related Target A Factor VIII (F8); co-factor in intrinsic tenase complex; hemophilia A counterpart for comparative studies. View Factor VIII Products
Related Target B Factor X (F10); physiological substrate of FIXa; critical for tenase complex reconstitution. View Factor X Products
Related Target C TFPI (Tissue Factor Pathway Inhibitor); non-factor rebalancing target for bypass therapy. View TFPI Products
Related Target D Factor VII (F7); initiator of extrinsic pathway; bypass therapy comparator. View Factor VII Products

Critical Assay Challenges & TarMart Advantage

Critical Assay Challenge The TarMart Advantage (Technical Spec)
Complex Post-Translational Modifications (PTMs) HEK293 expressed to preserve Gla domain γ-carboxylation and native glycosylation; high purity >95% strictly monitored.
Evaluating Hyperactive Variants (Gene Therapy) Sequence Verified Padua mutant (R338L) protein and ORF available for side-by-side benchmarking with wild-type.
Lack of Controls in PK/ADA Assays Clinical Benchmark Antibodies (biosimilar sequences) included as rigorous positive controls.
Off-target and Background Noise Validated siRNA included for precise specificity and knockdown checks.
Species Cross-Reactivity for Gene Therapy PK/PD Human, Cynomolgus, Mouse orthologs available; HEK293 expressed for authentic PTMs and Gla integrity.
Gla Domain Integrity Verification Calcium-binding competent full-length proteins; theoretical MW confirmed by mass spec.
Immunogenicity/Inhibitor Screening Clinical-grade purity (>95%) with endotoxin control (<1EU/µg) to eliminate false positive ADA results.
Sub-Q Formulation Stability High-concentration protein (up to 10 mg/mL) suitable for viscosity/aggregation screening.
Cellular Secretion & ER Processing (Gene Therapy Models) Lentivirus premade particles for stable hepatocyte line construction.

Live Factor IX (F9) R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The therapeutic landscape for Hemophilia B is undergoing a paradigm shift from prophylactic replacement to curative gene therapy and next-generation biologics. With the approval of AAV5-based Hemgenix (CSL/UniQure) and Pfizer's BEQVEZ, the competitive focus has intensified on vector immunogenicity reduction, ultra-pure protein formulations for extended half-life (EHL) Fc-fusions, and subcutaneous delivery strategies. The next wave of R&D prioritizes FIX variants with enhanced specific activity (e.g., Padua R338L) to reduce viral load, alongside CRISPR-based in vivo gene editing that bypasses AAV limitations. As first-generation replacement therapies reach clinical saturation, non-factor rebalancing agents (e.g., anti-TFPI, siRNA targeting antithrombin) are gaining traction for patients with inhibitors.

Key Functional Domains & Mutations (F9)

Factor IX (F9) is a vitamin K-dependent serine protease with multiple functional domains essential for coagulation (UniProt P00740):

  • Gla domain: Calcium-dependent phospholipid membrane binding, required for tenase complex assembly.
  • EGF-like domain 1 (calcium-binding): Mediates interaction with Factor VIIIa and structural stability.
  • EGF-like domain 2: Modulates protein interactions and activation.

Key mutations associated with Hemophilia B:

  • rs150190385: Variant of uncertain significance; decreased protein abundance and function.
  • HEMB; severe; UK 22: Severe disease-causing mutation with complete activity loss.
  • HEMB; uncertain significance: Decreased protein abundance and function.

The hyperactive Padua variant (R338L) increases specific activity ~5-8 fold and is widely adopted in gene therapy constructs.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
AAV Gene Therapy CSL/UniQure (Hemgenix), Pfizer (BEQVEZ), Sarepta (FLT180a) Hemophilia B (Severe) Potency/Purity of FIX-Padua antigen; species-specific PK ELISAs (Human/Cyno).
Extended Half-Life (EHL) Protein Sanofi (Alprolix), CSL Behring (Idelvion) Hemophilia B Prophylaxis Fc-fusion integrity analysis; high-concentration stability assays.
Bispecific Antibody Roche / Chugai (Hemlibra – mechanism relevance) Hemophilia A/B with Inhibitors Complex formation validation (need pure FIX/FIXa and FX).
siRNA / RNAi (Bypass) Sanofi (Alnylam) – Fitusiran Hemophilia (Pan) Coagulation rebalancing assays (need pure native cascade proteins).
Gene Editing (CRISPR) Intellia, Editas (Preclinical/Phase I) Hemophilia B (Functional Cure) Knock-in validation assays; FIX expression quantification standards.
mRNA Therapy Moderna (mRNA-6231, platform relevant) Hemophilia B In vitro translation validation; protein folding assays.